NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.10 million. Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. View Co-Diagnostics' Earnings History.

Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Co-Diagnostics.

2 equities research analysts have issued 1 year target prices for Co-Diagnostics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Co-Diagnostics' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Co-Diagnostics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.

Headlines about CODX stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Co-Diagnostics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Co-Diagnostics.

Co-Diagnostics saw a increase in short interest in December. As of December 13th, there was short interest totalling 600,200 shares, an increase of 9.3% from the November 28th total of 549,200 shares. Based on an average daily trading volume, of 74,500 shares, the short-interest ratio is currently 8.1 days. Approximately 5.6% of the company's stock are short sold. View Co-Diagnostics' Current Options Chain.

Some companies that are related to Co-Diagnostics include Liquidia Technologies (LQDA), BRAINSWAY LTD/S (BWAY), Spectral Medical (EDTXF), BeyondAirInc . (XAIR), Neuronetics (STIM), Nephros (NEPH), Nephros (NEPHD), Sensus Healthcare (SRTS), AIT Therapeutics (AITB), Pro-Dex (PDEX), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Apollo Endosurgery (APEN), PAVmed (PAVM) and T2 Biosystems (TTOO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), Sierra Oncology (SRRA), Inpixon (INPX), Bausch Health Companies (BHC), Nokia Oyj (NOK), AT&T (T), Advanced Micro Devices (AMD), FuelCell Energy (FCEL) and Kopin (KOPN).

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CODX stock can currently be purchased for approximately $1.88.

Co-Diagnostics has a market capitalization of $32.19 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics.

The official website for Co-Diagnostics is http://www.codiagnostics.com/.

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]